MedPath

Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

Early Phase 1
Recruiting
Conditions
PCOS
Polycystic Ovary Syndrome
Interventions
First Posted Date
2020-10-22
Last Posted Date
2023-11-02
Lead Sponsor
University of Virginia
Target Recruit Count
10
Registration Number
NCT04597099
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Low Dose Prednisone Therapy in Women With Recurrent Pregnancy Loss

Phase 2
Conditions
Recurrent Pregnancy Loss(RPL)
Recurrent Miscarriage
Interventions
Dietary Supplement: vit D
Dietary Supplement: Iron Supplement
Dietary Supplement: Folic Acid
First Posted Date
2020-09-22
Last Posted Date
2020-09-22
Lead Sponsor
Soroka University Medical Center
Target Recruit Count
242
Registration Number
NCT04558268
Locations
🇮🇱

Soroka Medical Center, Be'er Sheva, Israel

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

Phase 3
Recruiting
Conditions
Infertility
Interventions
Drug: Progesterone-IBSA Injectable Solution
Drug: Placebo Vaginal gel with applicator
Drug: Placebo injectable solution
First Posted Date
2020-09-16
Last Posted Date
2025-04-04
Lead Sponsor
IBSA Institut Biochimique SA
Target Recruit Count
680
Registration Number
NCT04549116
Locations
🇺🇸

The Fertility Treatment Center, LLC, Tempe, Arizona, United States

🇺🇸

HRC Fertility, Encino, California, United States

🇺🇸

Kindbody, Los Angeles, California, United States

and more 18 locations

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Phase 3
Completed
Conditions
Infertility, Female
Interventions
First Posted Date
2020-09-03
Last Posted Date
2022-02-17
Lead Sponsor
El Shatby University Hospital for Obstetrics and Gynecology
Target Recruit Count
90
Registration Number
NCT04537078
Locations
🇪🇬

Elshatby University Maternity Hospital, Alexandria, Egypt

Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen

Phase 2
Terminated
Conditions
Transgender Persons
Interventions
First Posted Date
2020-09-01
Last Posted Date
2024-03-19
Lead Sponsor
St. Louis University
Target Recruit Count
5
Registration Number
NCT04534881
Locations
🇺🇸

Saint Louis University, Saint Louis, Missouri, United States

The Outcome of Two Protocols Used to Prepare Endometrium for Frozen Embryo Transfer

Phase 4
Completed
Conditions
Infertility
Infertility, Female
Infertility, Male
Interventions
First Posted Date
2020-08-10
Last Posted Date
2022-04-27
Lead Sponsor
Rahem Fertility Center
Target Recruit Count
112
Registration Number
NCT04507022
Locations
🇪🇬

Rahem Fertility Center, Zagazig, Sharkia, Egypt

Impact of Different Doses and Routes of Exogenous Progesterone Administration on Endometrial Receptivity Parameters

Phase 4
Recruiting
Conditions
Infertility, Female
ENDOMETRIAL RECEPTIVITY
Interventions
Other: Artificial Cycle (no intervention)
First Posted Date
2020-08-05
Last Posted Date
2024-10-04
Lead Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Target Recruit Count
108
Registration Number
NCT04499131
Locations
🇪🇸

Instituto Valenciano de Infertilidad Spain, Valencia, Spain

Effect of Progesterone Therapy on Traumatic Subarachinoid Haemorrhage on Clinical Outcome and Resistive Vasculer Indices of Middle Cerebral Artery Transcranial Doppler

Early Phase 1
Conditions
Traumatic Brain Injury
Interventions
First Posted Date
2020-06-11
Last Posted Date
2020-06-11
Lead Sponsor
Minia University
Target Recruit Count
200
Registration Number
NCT04426487
Locations
🇪🇬

ElMinia University, Minya, Abohelal, Egypt

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

Phase 3
Completed
Conditions
IVF
GnRH Antagonist
PPOS
Interventions
First Posted Date
2020-06-04
Last Posted Date
2023-08-30
Lead Sponsor
ShangHai Ji Ai Genetics & IVF Institute
Target Recruit Count
784
Registration Number
NCT04414761
Locations
🇨🇳

ShangHai JIAI Genetics&IVF Institute, Shanghai, China

Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors

Phase 1
Conditions
Diffuse Traumatic Cerebral Edema
Interventions
First Posted Date
2020-06-04
Last Posted Date
2020-06-04
Lead Sponsor
Minia University
Target Recruit Count
26
Registration Number
NCT04414020
Locations
🇪🇬

Faculty of Medicine, Minya, Abohelal, Egypt

© Copyright 2025. All Rights Reserved by MedPath